Skip to main content

Sign in Register

Market DashboardMarkets, breadth and flows IndicesNSE & BSE benchmarks SectorsToday's rotation HeatmapSize = cap, colour = move BreadthAdvancers vs decliners FII/DIIInstitutional flows ValuationIs the market expensive?

SCREENER STOCKS FILINGS

Intelligence

Situations Conviction Broker Reports Earnings Deliveries Deals Corp. Actions

Discovery

Themes IPO Funds Community

PORTFOLIO MY AI

after·markets

Track what you own. Screen what you don't. India's market intelligence: screening, conviction scoring, and filing analysis, alive in real time.

Data: NSE & BSE

contact@aftermarkets.in

Markets

Market Dashboard
Screener
All Stocks
Heatmap
FII / DII

Research

Research hub
Filings
Conviction
Earnings
Broker Reports
Deliveries
Valuation
Deals
Themes
IPO Tracker
Funds & PMS

You

Portfolio
Trade Journal
Alerts
Watchlist
Get started

Company

About
Pricing
Learn
Developer / MCP
Terms
Privacy
Disclaimer

Operated by Chainlytics Advisory Services LLP.

© 2026 aftermarkets.in · Mumbai, IndiaInvestment in securities market are subject to market risks. Read all related documents carefully before investing.

Jubilant Pharmova Limited

NSE: JUBLPHARMA · Healthcare · Pharmaceuticals · Market cap ₹15,356 Cr

₹964.10▾−18.85 (−1.92%)

· Prev close ₹982.95 · Volume 54.76 K · 52W ₹786–1,162

13 Nov Sep-quarter results

Jubilant Pharmova ₹964.10 ▾−1.92%Results 13 Nov

⇧⌘K

Company research

Overview
Profitability2
Growth5
Valuation5
Financial health5
Ownership5
Price momentum6
Filings & calls9
Company8

Every dataset is a tab inside its group. Search finds any of them, including old names such as “concall”.
Find a dataset: Ctrl/⌘ Shift K
Find another stock: Ctrl/⌘ K

Jubilant Pharmova › Valuation

Valuation

Key figures Multiples & history All ratios Peer comparison Exit-multiple scenario

Loading selected research…

← PreviousGrowth · Triggers Next →Valuation · Multiples & history

: 43.4×; price ÷ EPS for the 4 quarters Sep 2025 to Jun 2026
: 16.9×; FY21–26
: 25.8×; 5 listed peers
Price / book: 2.2×; fundamentals feed
EV / EBITDA: 12.7×; fundamentals feed
Dividend yield (feed): 0.51%; fundamentals feed
Earnings yield: 2.3%; 1 ÷ P/E

P/E at each year-end and todaydashed: peers' median

————13×15×—118×17×33×43×

FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26Now

Peers' median 25.8×

Fiscal year-end readings only; intra-year highs and lows are not stored.

P/E, 6 listed peersranked, high to low

1AstraZeneca Pharma India84.8×
2CORONA Remedies68.8×
3Jubilant Pharmova43.4×
4Marksans Pharma25.8×
5Pfizer20.5×
6Natco Pharma12.7×

Median of the other 5: 25.8×

Exit-multiple scenario: set your own profit growth and exit P/E